GLP-1 Receptor Agonist vs GIP: What the Research Compares

Read the naming first: these labels sit at different levels

GLP-1 receptor agonist is a drug class name. It describes molecules that activate the glucagon-like peptide-1 receptor. GIP is the abbreviation for glucose-dependent insulinotropic polypeptide, a gut hormone released after eating, and in pharmacology writing the abbreviation is often extended to the GIP receptor and to agents that engage it. One term names a class of drugs, the other names a hormone and its target. That mismatch explains why a clean head-to-head comparison is hard to find in the literature.

The two names also overlap inside single molecules. Tirzepatide was engineered from a GIP peptide backbone and activates both the GIP receptor and the GLP-1 receptor, and researchers described that discovery path and early clinical proof of concept in a 2018 report on LY3298176 (PMID 30473097). A later molecule, LY3437943, extended the same design logic to three receptors, glucagon, GIP and GLP-1, in a 2022 discovery and early clinical report (PMID 35985340). So in much of the published work, GIP receptor agonism is not an alternative to GLP-1 receptor agonism but a component added alongside it.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or treatment.

Class, mechanism and status side by side

Head-to-head evidence: what exists and what does not

No trial compared GIP alone against a GLP-1 receptor agonist

Among the papers summarised here, none randomised participants to a GIP receptor agonist alone versus a GLP-1 receptor agonist alone. The comparative clinical data instead set a dual GIP and GLP-1 receptor agonist against a single-receptor GLP-1 agonist. Anyone searching for a direct GIP monotherapy versus GLP-1 monotherapy outcome trial will not find one in this evidence set.

Dual GIP and GLP-1 agonist versus dulaglutide

A randomised phase 2 trial published in 2018 tested LY3298176 at 1 mg, 5 mg, 10 mg and 15 mg once weekly against dulaglutide 1.5 mg and placebo over 26 weeks in people with type 2 diabetes, and the investigators reported greater reductions in HbA1c and body weight with the higher dual-agonist doses than with dulaglutide (PMID 30293770). A mechanistic analysis from that programme reported improvements in beta-cell function and insulin sensitivity with the dual GIP and GLP-1 receptor agonist in type 2 diabetes (PMID 33236115).

A cardiovascular outcome comparison was built on the same pairing. The SURPASS-CVOT design and baseline characteristics paper described an event-driven trial comparing tirzepatide with dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease (PMID 37758044). That design paper reported enrolment characteristics rather than outcomes, so it establishes the comparison structure rather than a result.

Dual agonist versus placebo

SURPASS-1, a double-blind randomised phase 3 trial, compared tirzepatide 5 mg, 10 mg and 15 mg once weekly with placebo over 40 weeks in people with type 2 diabetes not on background glucose-lowering therapy, and the study reported greater reductions in HbA1c and body weight in the tirzepatide groups than in the placebo group (PMID 34186022). A 2022 systematic review and meta-analysis of tirzepatide in type 2 diabetes pooled trials across comparators and reported glycaemic and weight outcomes alongside dose-related gastrointestinal adverse events (PMID 35579691).

Why GIP was added to GLP-1 in the first place

A 2020 review examined the rationale for combining the two incretin signals and asked how GIP might enhance the therapeutic efficacy of GLP-1, surveying proposed contributions to insulin secretion, adipose tissue handling and tolerability (PMID 32396843). Preclinical work added a tolerability hypothesis: a 2021 study in animal models reported that GIP receptor agonism attenuated nausea and emesis induced by GLP-1 receptor agonism (PMID 34380697). Those findings came from preclinical models and were not human outcome trials, a distinction the authors themselves framed in the title of that report (PMID 34380697).

Receptor pharmacology: the balance is not even

A comparison of the two targets is incomplete without the receptor-level detail. A 2020 pharmacology study characterised tirzepatide as an imbalanced and biased dual GIP and GLP-1 receptor agonist, reporting relatively weaker activity at the GLP-1 receptor than at the GIP receptor and a signalling profile at the GLP-1 receptor that favoured cAMP production over beta-arrestin recruitment (PMID 32730231). That observation matters for anyone treating "dual agonist" as a simple sum of two equal halves, because the study reported that the two arms of the molecule were not engaged to the same degree (PMID 32730231).

The engineering history points the same way. The 2018 discovery report described a peptide derived from a GIP sequence that was modified to acquire GLP-1 receptor activity, which is a different starting point from GLP-1 analogues built on the native GLP-1 sequence (PMID 30473097).

Body composition: where pooled analyses placed the classes

A 2025 systematic review and network meta-analysis examined the effect of GLP-1 receptor agonists and co-agonists on body composition, pooling randomised evidence across single-receptor and multi-receptor agents and reporting changes in fat mass and lean mass components of weight change (PMID 39719170). Network meta-analyses of this kind connect agents through shared comparators rather than through direct randomisation, so the review's own indirect-comparison caveats apply to any ranking read out of it (PMID 39719170).

Adverse Events: What Studies Report

Reported tolerability data in this evidence set come from the dual agonist trials rather than from GIP-only clinical programmes. SURPASS-1 reported that the most common adverse events with tirzepatide were gastrointestinal, including nausea, diarrhoea and vomiting, and that they were mostly mild to moderate (PMID 34186022). The 2022 systematic review and meta-analysis of tirzepatide in type 2 diabetes reported gastrointestinal adverse events that related to dose across the pooled trials (PMID 35579691). The 2018 phase 2 trial comparing LY3298176 with dulaglutide and placebo also reported gastrointestinal events as the predominant adverse-event category (PMID 30293770).

On cardiovascular safety, a pre-specified meta-analysis of tirzepatide trials assessed cardiovascular event risk and reported no increase in major adverse cardiovascular events in the pooled analysis (PMID 35210595). The dedicated outcome comparison against dulaglutide was described as an ongoing event-driven trial in its design publication (PMID 37758044), so a definitive head-to-head cardiovascular result is not contained in that paper.

What each evidence base covers

• Glycaemic endpoints: measured for the dual GIP and GLP-1 receptor agonist against placebo in phase 3 (PMID 34186022) and against dulaglutide in phase 2 (PMID 30293770).
• Beta-cell function and insulin sensitivity: reported in a dedicated analysis of the dual agonist in type 2 diabetes (PMID 33236115).
• Body composition: pooled across GLP-1 receptor agonists and co-agonists in a network meta-analysis (PMID 39719170).
• Receptor signalling: characterised in vitro, including the imbalanced and biased profile of the dual agonist (PMID 32730231).
• Nausea and emesis mechanisms: addressed in preclinical GIP receptor agonism models (PMID 34380697).
• Multi-receptor extension: a triple glucagon, GIP and GLP-1 receptor agonist was described from discovery through early clinical proof of concept (PMID 35985340).

Limitations worth keeping in view

1. The comparison is asymmetric. A drug class is being compared with a hormone target, and the clinical literature summarised here studied GIP receptor agonism mainly inside dual-agonist molecules (PMID 30473097).
2. Active-comparator data exist for one specific GLP-1 receptor agonist, dulaglutide, rather than for the class as a whole (PMID 30293770).
3. Design and baseline publications describe planned comparisons, not results (PMID 37758044).
4. Preclinical tolerability findings do not establish human outcomes (PMID 34380697).
5. Pooled analyses depend on the trials available to them and on indirect comparison assumptions (PMID 39719170).

No conclusion about superiority is drawn here, and none of the cited papers supports treating one target as a replacement for the other outside the specific populations and endpoints each trial studied (PMID 35579691).

Related reading

• GLP-1 receptor agonist: literature overview
• GIP: literature overview

References

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (Molecular Metabolism, 2018)
• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis (Metabolism, 2025)
• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis (Diabetologia, 2022)
• How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Trends in Endocrinology and Metabolism, 2020)
• GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models (Diabetes, 2021)
• Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (Lancet, 2018)
• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (Journal of Clinical Endocrinology and Metabolism, 2021)
• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis (Nature Medicine, 2022)